organization · Reporting owner
Flagship Pioneering Special Opportunities Fund II, L.P.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director · 10% owner | January 13, 2026 | January 15, 2026 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | 10% owner | February 26, 2026 | March 02, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | 10% owner | February 27, 2023 | February 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date January 13, 2026 · Filed January 15, 2026
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2046-01-13 | IndirectBy Flagship Pioneering Fund VII, L.P. | 2,235,468 |
Reported balance
After 2026-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-13 · Grant · Acquired 2,235,468 · Balance 2,235,468 F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 1 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.42 · Expires 2027-06-30 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 2 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.13 · Expires 2030-12-31 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.
F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
Jointly reported with Afeyan Noubar, Flagship VentureLabs VI LLC, Flagship Pioneering Fund VI, L.P., Flagship Pioneering Fund VII, L.P., Nutritional Health LTP Fund, L.P., FPN II, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VI, L.P. | 12,723,940 |
Reported balance
After 2026-03-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-03-02 · Conversion · Acquired 12,723,940 · Balance 12,723,940 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 15,264,724 |
Last balance in matching sequence
After 2026-03-02 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-03-02 · Conversion · Acquired 13,702,224 · Balance 13,702,224 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 6 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 15,264,724 F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 987,491 |
Reported balance
After 2026-03-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-03-02 · Conversion · Acquired 987,491 · Balance 987,491 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 2,777,752 |
Reported balance
After 2026-03-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy FPN II, L.P. | 4,340,252 |
Last balance in matching sequence
After 2026-03-02 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 5 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 7 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 4,340,252 F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Pioneering Medicines 02, LLC | 1,562,500 |
Reported balance
After 2026-03-02 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 1,562,500 F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-02 · Conversion · Disposed 18,483,785 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-02 · Conversion · Disposed 17,016,215 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Nutritional Health LTP Fund, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-02 · Conversion · Disposed 1,500,000 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-02 · Conversion · Disposed 843,881 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-02 · Conversion · Disposed 2,953,586 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-03-02 · Conversion · Disposed 2,531,644 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs VI, LLC | 25,016,458 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 25,016,458 F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.
F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Omega Therapeutics, Inc.
Report date February 27, 2023 · Filed February 27, 2023
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 7,508,693 |
Reported balance
After 2023-02-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-02-27 · Purchase · Acquired 1,993,986 · Balance 7,508,693 F1: On February 27, 2023, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,993,986 shares and 1,329,324 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023. F2: Represents shares held directly by Flagship Opportunities Fund II. Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,329,324 |
Reported balance
After 2023-02-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-02-27 · Purchase · Acquired 1,329,324 · Balance 1,329,324 F1: On February 27, 2023, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,993,986 shares and 1,329,324 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023. F3: Represents shares held directly by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 1,088,470 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,088,470 F4: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V Rx. Dr. Afeyan is the sole manager of Flagship V GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 5,896,386 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,896,386 F5: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship V GP is the general partner of Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VI, L.P. | 8,617,413 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 8,617,413 F6: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 970,588 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 970,588 F7: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy FPN, L.P. | 1,617,646 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 1,617,646 F8: Represents shares held directly by FPN, L.P. ("FPN Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN Fund. Flagship Pioneering is the manager of FPN GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V, LLC | 2,197,059 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 2,197,059 F9: Represents shares held directly by Flagship VentureLabs V, LLC ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 27, 2023, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,993,986 shares and 1,329,324 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023.
F2: Represents shares held directly by Flagship Opportunities Fund II. Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3: Represents shares held directly by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V Rx. Dr. Afeyan is the sole manager of Flagship V GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F5: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship V GP is the general partner of Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F6: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F7: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F8: Represents shares held directly by FPN, L.P. ("FPN Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN Fund. Flagship Pioneering is the manager of FPN GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F9: Represents shares held directly by Flagship VentureLabs V, LLC ("VentureLabs V"). VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sigilon Therapeutics, Inc.
Report date August 11, 2023 · Filed August 15, 2023
Jointly reported with Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering, LLC, Afeyan Noubar
Section 16 reporting ended · disclosed 2023-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 0 |
Reported balance
After 2023-08-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-08-11 · Other · Disposed 683,760 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split. F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-08-11 · Other · Disposed 113,960 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split. F4: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones.
F2: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split.
F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 20 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 19 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,531,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 18 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,666,651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 17 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,953,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 16 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,944,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 15 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 843,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 14 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 555,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 13 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 987,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 17,016,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 12 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 11,202,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 18,483,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 11 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 12,168,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 8 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pioneering Medicines 02, LLC Disclosed balance after: 1,562,500 F7 · ownership.nature: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 7 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 4,340,252 F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 6 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 15,264,724 F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 5 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 4 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 987,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 3 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 987,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 13,702,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 2 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 13,702,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 12,723,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 1 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 12,723,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | GrantStock Option (Right to Buy) · Derivative | 29,561 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 10 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F9 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 2 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $20.13 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 3 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2030-12-31 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 1 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $13.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 2 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2027-06-30 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantPre-Funded Warrants to purchase Common Stock · Derivative | 2,235,468 | $6.71 Strike: $0.00 | $14,999,766.73 |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 1 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 2,235,468 Underlying: Common Stock · 2,235,468 shares Expires 2046-01-13 F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:05 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchasePre-Funded Warrants to purchase Common Stock · Derivative | 1,814,915 | $5.51 Strike: $0.00 | $10,000,000.16 |
DisclosureSEC source: 0000950170-24-064713 · ownership.xml · derivative · entry 2 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,814,915 Underlying: Common Stock · 1,814,915 shares Expires not disclosed F1 · kind: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.exercise_date: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:05 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchasePre-Funded Warrants to purchase Common Stock · Derivative | 1,814,914 | $5.51 Strike: $0.00 | $9,999,994.65 |
DisclosureSEC source: 0000950170-24-064713 · ownership.xml · derivative · entry 1 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 1,814,914 Underlying: Common Stock · 1,814,914 shares Expires not disclosed F1 · kind: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.exercise_date: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F1 · derivative.expiration_date: On May 22, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants (the "Pre-Funded Warrants") to purchase 1,814,914 and 1,814,915 shares of Common Stock, respectively, at a purchase price of $5.5099 per Pre-Funded Warrant. The Pre-Funded Warrants are immediately exercisable and do not have an expiration date; however, a holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2 · ownership.nature: Securities held by Flagship Opportunities Fund II. Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | OtherCommon Stock | 113,960 | $14.92 | $1,700,283.20 |
DisclosureSEC source: 0000899243-23-018154 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F2 · shares: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:15 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | OtherCommon Stock | 683,760 | $14.92 | $10,201,699.20 |
DisclosureSEC source: 0000899243-23-018154 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Ventures Fund V, L.P. Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F2 · shares: Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The share amounts in this Form 4 have been adjusted for the Reverse Split. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger by and among the Issuer, Eli Lilly and Company and Shenandoah Acquisition Corporation, dated as of June 28, 2023, these shares were tendered in exchange for (a) $14.92 per share and (b) one contingent value right per Share (each, a "CVR"), which represents the contractual right to receive up to three contingent payments for an aggregate of up to $111.64 per CVR, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones. F3 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 27, 2023 Filed Feb 27, 2023 17:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 1,329,324 | $5.78 | $7,683,492.72 |
DisclosureSEC source: 0000899243-23-006241 · doc4.xml · nonDerivative · entry 2 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,329,324 F1 · kind: On February 27, 2023, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,993,986 shares and 1,329,324 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023. F3 · ownership.nature: Represents shares held directly by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| February 27, 2023 Filed Feb 27, 2023 17:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 1,993,986 | $5.78 | $11,525,239.08 |
DisclosureSEC source: 0000899243-23-006241 · doc4.xml · nonDerivative · entry 1 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 7,508,693 F1 · kind: On February 27, 2023, Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,993,986 shares and 1,329,324 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023. F2 · ownership.nature: Represents shares held directly by Flagship Opportunities Fund II. Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Opportunities Fund II disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 21 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 441,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 20 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,323,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 19 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 441,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 18 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 882,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 13,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 17 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,529,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 16 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 176,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 15 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 705,882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 14 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 794,118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 27,388,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 13 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 7,249,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 22,275,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 12 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 5,896,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,112,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 11 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,088,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 294,117 | $17.00 | $4,999,989.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 9 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,617,646 F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 1,323,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 8 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,323,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 661,764 | $17.00 | $11,249,988.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 7 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,514,707 F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 4,852,943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 6 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,852,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 970,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 5 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 970,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 220,588 | $17.00 | $3,749,996.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 4 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,617,413 F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 8,396,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 3 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,396,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 5,896,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 2 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,896,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 1,088,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 1 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,088,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 18:19 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,481,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-134302 · tm2037869-3_4seq1.xml · derivative · entry 6 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,481,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · kind: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · price: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · derivative.exercise_date: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · derivative.expiration_date: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F3 · ownership.nature: Shares held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is sole director of Flagship Pioneering. Each of Noubar B. Afeyan Ph.D., Flagship Pioneering, and Opportunities Fund II GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 18:19 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | ConversionSeries B Convertible Preferred Stock · Derivative | 370,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-134302 · tm2037869-3_4seq1.xml · derivative · entry 5 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 370,370 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · kind: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · price: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · derivative.exercise_date: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F1 · derivative.expiration_date: Upon closing of the Registrant's initial public offering, each share of Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock or Series B Convertible Preferred Stock. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.